This week PharmaShots’ news was all about the updates on Clinical Trials, Regulatory, Pharma, DigiHealth, MedTech, Biosimilars, Animal Health & Biotech. Check out our full report below:
Novo Nordisk Reports Headline Results from P-IIIb (STEP UP) Study of Semaglutide 7.2mg in Obese Adults without Diabetes
Read More: Novo Nordisk
Yoltech Initiates a Dose-Escalation Study for YOLT-204 to Treat…
Shots:
The EMA’s CHMP has granted positive opinions to 5 Biologics and 4 New Chemical Entities in December 2024, leading to treatments for patients and advances in the healthcare industry
The major highlighted drugs were Galderma’s Nemluvio to treat Prurigo Nodularis and Atopic Dermatitis
PharmaShots has compiled a list of 9 drugs that have been granted positive…
This week PharmaShots’ news was all about the updates on Clinical Trials, Regulatory, Pharma, MedTech, M&A, Biosimilars, Animal Health & Biotech. Check out our full report below:
Bayer Reports Topline Data from P-III (QUANTI) Trials of Gadoquatrane for its Use in MRI
Read More: Bayer
Oryzon Reports Dosing of the First Patient with Iadademstat + Venetoclax + Azacitidine…
Shots:
The January Edition features RA Capital Management, a global multi-stage investment firm dedicated to healthcare and life sciences
In 2024, RA Capital added 74 companies to its portfolio, investing approximately $8.5B across seven funding rounds, including private and common funding
Welcome to the 2025 series of Know Your Investor, a meticulously crafted report highlighting…
Shots:
PharmaShots has compiled a list of US FDA-approved drugs in the month of December 2024
The US FDA has approved a total of 10 new drugs including 4 new molecular entities and 6 biologics leading to the treatment of patients and advances in the healthcare industry
The major highlighted drug was BMS’ Opdivo Qvantig…
Shots:
The Fourth quarter of 2024 highlights major acquisitions in the pharma and biotech industry along with clinical trial results and approvals. The highlight of the quarter was Roche's acquisition of Poseida Therapeutics for ~$1.5B
This quarter also showcased multiple clinical trial results including Pfizer's P-III Study Data of Talzenna + Xtandi to treat mCRPC …
This week PharmaShots’ news was all about the updates on Clinical Trials, Regulatory, Pharma, MedTech, M&A, Biosimilars, Animal Health & Biotech. Check out our full report below:
Oculis Reports Results from P-II (ACUITY) Study of OCS-05 for Treating Acute Optic Neuritis
Read More: Oculis
PharmaEssentia Reports Topline Data from P-III (SURPASS-ET) Trial of Ropeginterferon Alfa-2b-Njft (P1101) in Essential…
For the past two months, we focused on US Healthcare and the European Healthcare systems. This month we are explored China’s Healthcare system by diving deep into the intricacies of government schemes, regulatory reforms, and trends and practices. In 2023, China spent around 5.4% of its GDP to boost healthcare services across its provinces.
In…
Shots:
The first dose of the J.P. Morgan Special: Dealmaker of the Year report based on the total number of deals signed in 2024
Last year, Roche inked 38 deals comprising acquisitions, contract services, development & commercialization, facility purchase, R&D, platform/product purchases, and sales/co-promotion
Leveraging DealForma’s invaluable insights, PharmaShots brings an on-demand report…
Shots:
The first dose of the J.P. Morgan Special: Dealmaker of the Year report based on the total number of deals signed in 2024
Last year, Roche inked 38 deals comprising acquisitions, contract services, development & commercialization, facility purchase, R&D, platform/product purchases, and sales/co-promotion
Leveraging DealForma’s invaluable insights, PharmaShots brings an on-demand report on the Dealmaker…

